My Cart

Human CD40 (Luc) HEK293 Reporter Cell

Customer Reviews
Cat. No. / Size
Price
Qty
CHEK-ATF097-2Vials (1Vial X 2)
$14220.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • Description

    The Human CD40 (Luc) HEK293 Reporter Cell was engineered to not only express NF-κB signaling response element, but also express the receptor full length human CD40 (Uniprot: P25942-1), which can drive luciferase expressing systems by CD40 ligand/ agonist antibody stimulation. In the absence of agonist antibody or CD40 ligand, the CD40 receptor is not activated and luminescence signal is low. In the presence of agonist antibody or CD40 ligand, the CD40 pathway-activated luminescence can be detected in a dose-dependent manner. This reporter cell can also be used to test agonist antibody whether in an FcγR-dependent manner to strengthen the agonistic activity.

  • Application

    • Screen for ligands or agonist antibodies that can bind and activate CD40.

    CD40 Assay Principles

  • Growth Properties

    Adherent

  • Selection Marker

    Puromycin (2 μg/mL) + Hygromycin B (20 μg/mL)

  • Complete Growth Medium

    DMEM medium + 10% FBS

  • Freeze Medium

    Serum-free cell cryopreservation medium

  • Quantity

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • Storage

    Frozen in liquid nitrogen.

  • Mycoplasma Testing

    Negative

  • Sterility Testing

    Negative

  • Instructions for Use

    See data sheet for detailed culturing and assay protocol.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Receptor Assay

     CD40 FACS

    Expression analysis of human CD40 on Human CD40 (Luc) HEK293 Reporter Cell by FACS.
    Cell surface staining was performed on Human CD40 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human CD40 antibody.

    Protocol
  • Application

     CD40 APPLICATION

    Agonistic activity analysis of anti-human CD40 antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO or CHO/CD32b. Sotigalimab could depend on CD32b-mediated crosslinking to strengthen CD40 signaling. The EC50 of Sotigalimab in the presence of CHO/CD32b was approximately 0.079 μg/mL.

    Protocol
  •  CD40 APPLICATION

    Inhibition of human CD40 ligand protein-induced reporter activity by anti-human CD40 ligand neutralizing antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of human CD40 ligand protein with a final concentration of 0.1 μg/mL. The EC50 of anti-human CD40 ligand neutralizing antibody (Frexalimab) was approximately 0.26 μg/mL.

    Protocol
  • Signaling Bioassay

     CD40 SIGNALING

    Response to anti-human CD40 antibody (RLU).
    The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human CD40 antibody. The EC50 was approximately 0.096 μg/mL.

    Protocol
  •  CD40 SIGNALING

    Response to anti-human CD40 antibody (FOLD).
    The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human CD40 antibody. The max induction fold was approximately 14.

    Protocol
  •  CD40 SIGNALING

    Response to human CD40 ligand protein (RLU).
    The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human CD40 ligand protein. The EC50 was approximately 0.024 μg/mL.

    Protocol
  •  CD40 SIGNALING

    Response to human CD40 ligand protein (FOLD).
    The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human CD40 ligand protein. The max induction fold was approximately 9.16.

    Protocol
  • Passage Stability

     CD40 PASSAGE

    Passage stability analysis by Signaling Bioassay.
    The continuously growing Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human CD40 antibody. Anti-human CD40 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 6-22.

    Protocol
*Please contact us if you are interested in related cell pool service.

Customer Reviews
Writing Reviews

Important Statement

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor receptor superfamily member 5

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    46 Details

  • Highest Development Stage:

    Phase 3 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Important Statement
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland